262 related articles for article (PubMed ID: 29656760)
1. Successful treatment with brigatinib in a patient with ALK-rearranged lung adenocarcinoma who developed crizotinib-induced interstitial lung disease.
Doménech M; Jové M; Aso S; Marín M; Nadal E
Lung Cancer; 2018 May; 119():99-102. PubMed ID: 29656760
[TBL] [Abstract][Full Text] [Related]
2. Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer.
Camidge DR; Kim HR; Ahn MJ; Yang JC; Han JY; Lee JS; Hochmair MJ; Li JY; Chang GC; Lee KH; Gridelli C; Delmonte A; Garcia Campelo R; Kim DW; Bearz A; Griesinger F; Morabito A; Felip E; Califano R; Ghosh S; Spira A; Gettinger SN; Tiseo M; Gupta N; Haney J; Kerstein D; Popat S
N Engl J Med; 2018 Nov; 379(21):2027-2039. PubMed ID: 30280657
[TBL] [Abstract][Full Text] [Related]
3. Brigatinib versus crizotinib for ALK-positive NSCLC.
Stirrups R
Lancet Oncol; 2018 Nov; 19(11):e585. PubMed ID: 30293790
[No Abstract] [Full Text] [Related]
4. Management of Central Nervous System Metastases in Patients With Advanced Anaplastic Lymphoma Kinase-Rearranged Non-Small-Cell Lung Cancer During Crizotinib Treatment.
Zhao Y; Zhang B; Wang S; Qiao R; Xu J; Zhang L; Zhang Y; Han B
Clin Lung Cancer; 2019 Nov; 20(6):e631-e637. PubMed ID: 31362880
[TBL] [Abstract][Full Text] [Related]
5. Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial.
Camidge DR; Kim HR; Ahn MJ; Yang JCH; Han JY; Hochmair MJ; Lee KH; Delmonte A; García Campelo MR; Kim DW; Griesinger F; Felip E; Califano R; Spira A; Gettinger SN; Tiseo M; Lin HM; Gupta N; Hanley MJ; Ni Q; Zhang P; Popat S
J Clin Oncol; 2020 Nov; 38(31):3592-3603. PubMed ID: 32780660
[TBL] [Abstract][Full Text] [Related]
6. Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial.
Gettinger SN; Bazhenova LA; Langer CJ; Salgia R; Gold KA; Rosell R; Shaw AT; Weiss GJ; Tugnait M; Narasimhan NI; Dorer DJ; Kerstein D; Rivera VM; Clackson T; Haluska FG; Camidge DR
Lancet Oncol; 2016 Dec; 17(12):1683-1696. PubMed ID: 27836716
[TBL] [Abstract][Full Text] [Related]
7. Lorlatinib Salvages CNS Relapse in an ALK-Positive Non-Small-Cell Lung Cancer Patient Previously Treated With Crizotinib and High-Dose Brigatinib.
Sakamoto MR; Honce JM; Lindquist DL; Camidge DR
Clin Lung Cancer; 2019 Mar; 20(2):e133-e136. PubMed ID: 30578110
[No Abstract] [Full Text] [Related]
8. Brigatinib in patients with ALK-positive advanced non-small-cell lung cancer pretreated with sequential ALK inhibitors: A multicentric real-world study (BRIGALK study).
Descourt R; Perol M; Rousseau-Bussac G; Planchard D; Mennecier B; Wislez M; Cortot A; Guisier F; Galland L; Dô P; Schott R; Dansin E; Arrondeau J; Auliac JB; Chouaid C
Lung Cancer; 2019 Oct; 136():109-114. PubMed ID: 31491676
[TBL] [Abstract][Full Text] [Related]
9. Brigatinib and lorlatinib: their effect on ALK inhibitors in NSCLC focusing on resistant mutations and central nervous system metastases.
Naito T; Shiraishi H; Fujiwara Y
Jpn J Clin Oncol; 2021 Jan; 51(1):37-44. PubMed ID: 33147606
[TBL] [Abstract][Full Text] [Related]
10. Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial.
Kim DW; Tiseo M; Ahn MJ; Reckamp KL; Hansen KH; Kim SW; Huber RM; West HL; Groen HJM; Hochmair MJ; Leighl NB; Gettinger SN; Langer CJ; Paz-Ares Rodríguez LG; Smit EF; Kim ES; Reichmann W; Haluska FG; Kerstein D; Camidge DR
J Clin Oncol; 2017 Aug; 35(22):2490-2498. PubMed ID: 28475456
[TBL] [Abstract][Full Text] [Related]
11. Lung Toxicity in Non-Small-Cell Lung Cancer Patients Exposed to ALK Inhibitors: Report of a Peculiar Case and Systematic Review of the Literature.
Pellegrino B; Facchinetti F; Bordi P; Silva M; Gnetti L; Tiseo M
Clin Lung Cancer; 2018 Mar; 19(2):e151-e161. PubMed ID: 29174221
[TBL] [Abstract][Full Text] [Related]
12. Brigatinib: New-generation ALK inhibitor for nonsmall cell lung cancer.
Umbela S; Ghacha S; Matuknauth R; Gause S; Joshee S; Deshmukh RR
Curr Probl Cancer; 2019 Dec; 43(6):100477. PubMed ID: 31109722
[TBL] [Abstract][Full Text] [Related]
13. Intra-cranial efficacy of brigatinib in an ALK-positive non-small cell lung cancer patient presenting leptomeningeal carcinomatosis.
Gaye E; Geier M; Bore P; Guilloïque M; Lucia F; Quéré G; Gouva S; Robinet G; Descourt R
Lung Cancer; 2019 Jul; 133():1-3. PubMed ID: 31200813
[TBL] [Abstract][Full Text] [Related]
14. Molecular inhibitory mechanism study on the potent inhibitor brigatinib against four crizotinib-resistant ALK mutations.
Tu J; Song LT; Liu RR; Zhai HL; Wang J; Zhang XY
J Cell Biochem; 2019 Jan; 120(1):562-574. PubMed ID: 30191596
[TBL] [Abstract][Full Text] [Related]
15. Clinical activity of brigatinib in ROS1-rearranged non-small cell lung cancer.
Dudnik E; Agbarya A; Grinberg R; Cyjon A; Bar J; Moskovitz M; Peled N;
Clin Transl Oncol; 2020 Dec; 22(12):2303-2311. PubMed ID: 32462394
[TBL] [Abstract][Full Text] [Related]
16. Intracranial remission with brigatinib rechallenge as fifth-line ALK inhibition therapy in a lung cancer patient.
Hochmair M; Weinlinger C; Prosch H
Anticancer Drugs; 2019 Nov; 30(10):1058-1060. PubMed ID: 31033499
[TBL] [Abstract][Full Text] [Related]
17. Crizotinib-induced osteitis mimicking bone metastasis in a stage IV ALK-rearranged NSCLC patient: a case report.
Guisier F; Piton N; Bellefleur M; Delberghe N; Avenel G; Angot E; Vittecoq O; Ould-Slimane M; Morisse-Pradier H; Salaun M; Thiberville L
BMC Cancer; 2020 Jan; 20(1):14. PubMed ID: 31906956
[TBL] [Abstract][Full Text] [Related]
18. Interstitial lung disease secondary to alectinib after interstitial injury induced by crizotinib.
Kaira K; Naruse I; Shimizu K; Asao T
J Cancer Res Ther; 2020; 16(4):919-921. PubMed ID: 32930141
[TBL] [Abstract][Full Text] [Related]
19. Exploratory Analysis of Brigatinib Activity in Patients With Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer and Brain Metastases in Two Clinical Trials.
Camidge DR; Kim DW; Tiseo M; Langer CJ; Ahn MJ; Shaw AT; Huber RM; Hochmair MJ; Lee DH; Bazhenova LA; Gold KA; Ou SI; West HL; Reichmann W; Haney J; Clackson T; Kerstein D; Gettinger SN
J Clin Oncol; 2018 Sep; 36(26):2693-2701. PubMed ID: 29768119
[TBL] [Abstract][Full Text] [Related]
20. An evaluation of brigatinib as a promising treatment option for non-small cell lung cancer.
Hamilton G; Hochmair MJ
Expert Opin Pharmacother; 2019 Sep; 20(13):1551-1561. PubMed ID: 31328968
[No Abstract] [Full Text] [Related]
[Next] [New Search]